Fluid Around the Lung: When an Effusion Points to Cancer

This post walks the finding in the order the workup runs: why fluid collects, how the lab sorts it, what cytology can and cannot prove, when the answer has to come from tissue, and what changes if the effusion is malignant. Most effusions are not cancer. The ones that are deserve a full workup, not a single tap.

Why fluid collects around the lung

The pleural space is the thin gap between the lung and the chest wall, normally holding just enough fluid to let the two surfaces slide. An effusion means that balance broke: something is pushing fluid in, or something is inflaming the lining so it leaks and drains poorly. Pleural effusion is the most common pleural disease, affecting roughly 1.5 million patients a year in the United States (per StatPearls, NIH). The leading causes in adults are heart failure, infection, malignancy, and pulmonary embolism (per American Family Physician, 2023). That order matters, because the most common answer is also the least frightening one. Symptoms are unhelpfully generic: breathlessness most often, sometimes cough or chest discomfort, sometimes nothing at all.

How the fluid gets found depends on the picture taken. A standard upright chest X-ray needs about 200 mL before the costophrenic angle blunts. A lateral upright view catches as little as 50 mL, a lateral decubitus view 10 to 25 mL, and bedside ultrasound about 20 mL (per American Family Physician, 2023). CT is the study that describes the pleura itself, looking for thickening or nodularity rather than just fluid, and if your report reads like a foreign language, our guide on how to read a CT scan report breaks down the phrasing. Worth knowing early: a CT that looks clean does not exclude malignancy (per American Family Physician, 2023).

The first fork in the road: exudate or transudate

Almost every new, unexplained effusion of meaningful size gets a diagnostic thoracentesis, a needle draw of the fluid, usually under ultrasound guidance. In practice the threshold is an effusion larger than about 1 cm on lateral decubitus film or 2 cm on ultrasound or CT, with an exception for small bilateral effusions in someone clearly in decompensated heart failure, cirrhosis, or kidney failure (per American Family Physician, 2023). The ATS, STS, and STR joint guideline on malignant pleural effusions recommends ultrasound to guide pleural interventions (ATS/STS/STR, 2018).

What comes back gets sorted into two buckets by Light's criteria. The fluid counts as an exudate if any one of three things is true: the pleural to serum protein ratio is above 0.5, the pleural to serum LDH ratio is above 0.6, or the pleural LDH is above two thirds of the upper limit of normal for serum LDH (per American Family Physician, 2023). Nothing met means transudate, which points toward pressure problems like heart failure or cirrhosis. Anything met means exudate, which opens the door to infection, inflammation, and cancer.

Here is the part people miss. Light's criteria is close to 100% sensitive for exudates, which is why it is used, but it is not very specific: about 20% of heart failure patients on diuretics produce fluid ratios that read as exudative (per American Family Physician, 2023). An exudate label is a reason to keep going, not a finding in itself.

Why one negative tap does not settle the question

Cytology is the test that can prove a malignant effusion outright. A pathologist looks for cancer cells in the fluid, and finding them is definitive. Not finding them is not. Pleural fluid cytology is positive in about 60% of malignant pleural effusions (per American Family Physician, 2023). Read that the right way around: roughly two in five people who genuinely have a malignant effusion get a negative first result. That is not a lab error, it is the nature of the test. Cells shed into fluid unevenly, and yield varies by tumor type.

Repeating the tap helps, up to a point. In published series, a second specimen sent after a non-contributory first one is diagnostic in a meaningful additional share of cases, while a third adds considerably less. StatPearls notes that three samples taken on separate days push the success rate as high as 90% (per StatPearls, NIH). Volume matters too, and there is a real number attached: the British Thoracic Society recommends sending at least 25 mL, and where possible 50 mL, for the initial cytological examination, noting reduced sensitivity below that (per the BTS pleural disease guideline, 2023). So a tap that produced a thimble of fluid and a negative report is a weaker negative than one that sent a proper sample, and almost nobody tells the patient which one they had.

When the answer has to come from tissue

If cytology stays negative and the clinical suspicion of cancer does not go away, the workup moves from liquid to tissue.

Thoracoscopy is the highest-yield option. A camera goes into the pleural space, the operator sees the lining, and biopsies come from the abnormal areas rather than blindly. It is diagnostic in about 90% of patients whose cytology was negative (per American Family Physician, 2023). Image-guided needle biopsy, using CT or ultrasound to target thickened or nodular pleura, is less invasive and lands lower. The difference is not skill, it is sight. A needle aimed at fluid alone has nothing to aim at.

So "we tapped it and it was negative" is a stage of the workup, not the end of it. If the CT also described a nodule alongside the fluid, that finding carries its own follow-up schedule, which our guide on how lung nodule follow-up actually works lays out.

What a malignant effusion actually changes

Malignant pleural effusion complicates the care of roughly 150,000 people a year in the United States, and the most common primaries behind it are lung cancer and breast cancer, with lymphoma, gastrointestinal, and ovarian cancers also common (per American Family Physician, 2023).

In lung cancer, the effusion is not just a symptom, it is a staging descriptor. An effusion considered malignant makes the disease M1a, which is stage IV, and it counts whether or not cytology proved it, because the classification follows clinical judgment when the picture is convincing (per the AJCC TNM staging classification for lung cancer). There is a narrow, explicitly written exception: when repeated microscopic examinations are negative, the fluid is non-bloody and not an exudate, and clinical judgment says the effusion is unrelated to the tumor, it should be excluded as a staging descriptor. Both directions of that rule turn on how carefully the negatives were collected and read.

Management then follows symptoms rather than the picture. For a malignant effusion causing no symptoms, the ATS, STS, and STR panel recommended against performing pleural interventions (ATS/STS/STR, 2018). For breathlessness, options run from repeated drainage to an indwelling pleural catheter to pleurodesis, and the choice depends on whether the lung re-expands once the fluid is out.

How Healz reads a pleural effusion workup

Frontier AI works your case, so a negative cytology is read next to the CT description of the pleura, the protein and LDH ratios, the volume of fluid actually sent, and the history that raised the question. That is where effusion workups quietly fail. It is a reading problem before it is a testing problem.

The whole case sits in one chat. As an ai ct scan analysis reader, Healz is equipped to take the chest CT report and the pleural fluid numbers together, so pleural thickening or nodularity is weighed against the fluid chemistry rather than sitting in a different portal. Healz is equipped with root-cause technology, which is why it cross-checks your case against more than a million rare cases and drills past the first label to the cause underneath. Healz has memory that keeps every report you upload and connects them over time, so an effusion that returns three months later reads as a pattern, not a fresh surprise. One place, one chat, not ten apps. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.